by David N. Franz, MD; Gary W. Mathern, MD; and Elizabeth A. Thiele, MD, PhD
Epilepsy is the most common neurologic manifestation of TSC, affecting 80% to 90% of patients with the disease, with high rates of treatment resist......READ MORE
by David N. Franz, MD; Gary W. Mathern, MD; and Elizabeth A. Thiele, MD, PhD
Tuberous sclerosis complex (TSC) may manifest across a number of different organs, and there may be neurodevelopmental impact as well. As such, str......READ MORE
by David N. Franz, MD; Gary W. Mathern, MD; and Elizabeth A. Thiele, MD, PhD
Our featured experts provide an overview of the role of mammalian target of rapamycin (mTOR) inhibitor therapy in targeting the underlying pathophy......READ MORE
by David N. Franz, MD; Gary W. Mathern, MD; and Elizabeth A. Thiele, MD, PhD
Our knowledge of tuberous sclerosis complex (TSC) has expanded greatly with the discovery of the critical role of dysregulated mammalian target of ......READ MORE
